Pre Test

Please answer the following questions to gain access to the PDF.

1. What was the primary condition being treated in RISE and RIDE, VIVID and VISTA, and Protocol T studies?
    Diabetic macular edema
    Proliferative diabetic retinopathy
    Nonproliferative Diabetic Retinopathy
    Age-related macular degeneration
2. What were the two different dosing schedules of aflibercept compared with in the VIVID and VISTA studies?
    Sham injection
    Dexamethasone implant
3. CASE 1 DISCUSSION: A 55-year-old woman with a history of diabetes. A small percentage of patients with DME fail to respond to anti-VEGF therapy. In this case, the patient received 5 monthly injections of bevacizumab (1.25 mg) after which she was switched to monthly injections of ranibizumab (0.3 mg).
If the macular edema in a patient with diabetes fails to respond after 5 or 6 anti-VEGF injections, which next step might be most appropriate?
    Watch and wait for the vascularization to progress
    Look for alternative causes of inflammation
    Switch to a third anti-VEGF agent
    Perform a vitrectomy
4. CASE 2 DISCUSSION: PDR and DME frequently occur together, with an estimated 70% of patients with severe PDR eventually developing DME. The patient in this case has PDR and profound macular edema in his left eye. Visual acuity is 20/30 in both eyes. There is a small amount of NVE (neovascularization elsewhere) but no other vascularization.
In a reliable patient with diabetic macular edema and proliferative diabetic retinopathy with limited vascularization, which treatment strategy was favored by the panel experts?
    Watch and wait for the vascularization to progress
    First treat with anti-VEGF, then with laser if needed
    Laser only
    Laser combined with steroids
5. CASE 3 DISCUSSION: This was a 65-year-old patient with nonproliferative diabetic retinopathy of both eyes. The left eye was treated previously with focal laser and 3 injections of bevacizumab. The angio¬gram demonstrates diffuse leakage and cystoid edema. No areas of active neovasculariza¬tion were detected.
In patients with diabetic macular edema who are recalcitrant, retreatment with an anti-VEGF agent may help to extend the interval between:
    Steroid injections
    Laser treatments
    Office visits